Publications
5813 Results
- Journal / Conference
- Blood Advances 2026 May 8:bloodadvances.2026019616. doi: 10.1182/bloodadvances.2026019616
- Year
- 2026
- Research Committee(s)
- Leukemia
- PMID
- 42101912
- Study Number(s)
- C10403
Long-Term Follow-up of an Intensive Pediatric Regimen for Adolescents/Young Adults with Ph-negative Acute Lymphoblastic Leukemia: 10-year Survival Following CALGB 10403 (Alliance)
- Journal / Conference
- Cancers (Basel). 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373.
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41681846
- PMC
- PMC12896856
- Study Number(s)
- CTSU/A221504
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study
- Journal / Conference
- Journal for the ImmunoTherapy of Cancer 2026 Feb 11. 14:e012805. doi:10.1136/jitc-2025-012805.
- Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- 41672597
- Study Number(s)
- S1609
DART/SWOG/NCI phase II anti- CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
- Journal / Conference
- Journal of Clinical Oncology. 2026 June 3 epub. DOI: 10.1200/JCO-25-01896
- Year
- 2026
- Research Committee(s)
- Lung
- Study Number(s)
- LUNGMAP
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8669 poster
- Year
- 2026
- Research Committee(s)
- Lung
- Study Number(s)
- S1800E
Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)
- Journal / Conference
- JAMA Network Open, Apr 10, 2026;9(4):e264901. doi:10.1001/jamanetworkopen.2026.4901
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41961500
- PMC
- PMC13069458
- Study Number(s)
- S1714
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714
- Journal / Conference
- Popul Health Manag. 2025 Dec;28(6):313-321. doi: 10.1089/pop.2022.0143. Epub 2023 Jan 10.
- Year
- 2025
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID36625863
- Study Number(s)
- S0000
Racial and Ethnic Disparity in Preference-Weighted Quality of Life: Findings from the Selenium and Vitamin E Cancer Prevention Trial
- Journal / Conference
- Cancer 2025 Jan 1;131(1):e35587. doi: 10.1002/cncr.35587. Epub 2024 Sep 29.
- Year
- 2025
- Research Committee(s)
- Melanoma
- PMID
- PMID39342463
- PMC
- PMC11694162
- Study Number(s)
- S0826
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma
- Journal / Conference
- Blood Jan 2;145(1):75-84
- Year
- 2025
- Research Committee(s)
- Myeloma
- PMID
- PMID39321347
- Study Number(s)
- S0777, S1211
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
- Journal / Conference
- Breast Cancer Research and Treatment Feb;209(3):603-611
- Year
- 2025
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID39560823
- Study Number(s)
- S0927, S1200, S1202